Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Third party research

Lipum: Finding financial support - VH Corp

Lipum

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
* Preparations progress as planned
* Loan facilities provide support for 2025
* Our model suggests a fair value of SEK 16.29 per share

Lipum reported in its Q2 report that the manufacturing process of SOL-116 is nearing the final phase. The drug candidate is now being produced according to GMP standards, and the last batch is underway. At the same time, some of the company's major shareholders have provided short-term loans to finance the activities for the rest of the year. Shortly, we expect Lipum to announce a plan for financing the upcoming phase II study, which we now expect to start in Q2 2026.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.